Zhongguancun: Subsidiary company's tramadol hydrochloride tablets passed consistency evaluation.

Zhongguancun announced that its subsidiary Beijing Huasu Pharmaceutical recently received a notification from the National Medical Products Administration, stating that its production of "Tramadol Hydrochloride Tablets" has passed the evaluation of generic drug quality and efficacy consistency. There are already 8 generic drugs approved for market in China, with 3 of them passing the consistency evaluation, and Beijing Huasu is the fourth. As of the disclosure date of the announcement, the project has invested approximately 5.9 million yuan in research and development expenses. This evaluation is beneficial for enhancing drug competitiveness, having a positive impact on performance, and accumulating experience for future work. However, drug sales are influenced by various factors and there is uncertainty.